ARPO Aerpio Pharmaceuticals Inc

DGAP-News: One Square Advisory Services GmbH: Singulus Technologies AG (ISIN: DE000A2AA5H5) - Information an die Anleihegläubiger

DGAP-News: One Square Advisory Services GmbH / Schlagwort(e): Anleihe
One Square Advisory Services GmbH: Singulus Technologies AG (ISIN: DE000A2AA5H5) - Information an die Anleihegläubiger

25.01.2019 / 18:12
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.

One Square Advisory Services GmbH: Singulus Technologies AG (ISIN: DE000A2AA5H5) - Information an die Anleihegläubiger

München, 25. Januar 2019 - Die Singulus Technologies AG hat heute folgende Corporate News veröffentlicht:

 

"Die SINGULUS TECHNOLOGIES AG (SINGULUS TECHNOLOGIES) gibt bekannt, dass gemäß § 8 der Anleihebedingungen der Schuldverschreibungen (ISIN DE000A2AA5H5/ WKN A2AA5H), gegebenenfalls eine Finanzverbindlichkeit in Höhe von bis zu EUR 4.000.000,00 in Form eines Darlehens aufgenommen werden soll.

Gemäß § 8 (a) (iv) der Anleihebedingungen ist das Unternehmen verpflichtet, die Absicht der Aufnahme einer solchen Finanzverbindlichkeit mindestens zehn (10) Werktage vorher öffentlich per DGAP-Meldung bekannt zu machen."

Für Rückfragen steht die One Square Advisory Services GmbH, den Anleihegläubigern der Singulus Technologies AG, insbesondere unter , zur Verfügung.

 

Kontakt

One Square Advisory Services GmbH
Theatinerstr. 36
80333 München


25.01.2019 Veröffentlichung einer Corporate News/Finanznachricht, übermittelt durch DGAP - ein Service der EQS Group AG.
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.

Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten, Corporate News/Finanznachrichten und Pressemitteilungen.
Medienarchiv unter

769831  25.01.2019 

fncls.ssp?fn=show_t_gif&application_id=769831&application_name=news&site_id=research_pool
DE
25/01/2019

Underlying

ARPOAerpio Pharmaceuticals Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aerpio Pharmaceuticals Inc

 PRESS RELEASE
Free
ARPO Aerpio Pharmace...

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes

Aadi Bioscience to Join Russell 2000® and Russell 3000® Indexes LOS ANGELES, June 23, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced it will join both the U.S. small cap Russell 2000® Index and broad-market Russell 3000® Index at the conclusion of the 2022 Russell indexes annual reconstitution, effective immediately after the U.S. market opens on June 24, 2022 according to a preliminary list of add...

June 23, 2022 1 EN
 PRESS RELEASE
Free
ARPO Aerpio Pharmace...

Aadi Bioscience to Present at the Jefferies Global Healthcare Conferen...

Aadi Bioscience to Present at the Jefferies Global Healthcare Conference LOS ANGELES, June 01, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced members of the Aadi senior management team will participate in the Jefferies Global Healthcare Conference, to be held in New York, NY June 8-10, 2022. Founder, Chief Executive Officer and President, Neil Desai, Ph.D. is scheduled to present live during a fire...

June 1, 2022 1 EN
 PRESS RELEASE
Free
ARPO Aerpio Pharmace...

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor R...

Aadi Bioscience Appoints Marcy Graham Senior Vice President Investor Relations and Corporate Communications LOS ANGELES, May 31, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced the appointment of Marcy Graham to the new position of Senior Vice President, Investor Relations (IR) and Corporate Communications. “We are delighted to welcome Marcy to the team, as she brings extensive experience to ...

May 31, 2022 1 EN
 PRESS RELEASE
Free
ARPO Aerpio Pharmace...

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in ...

Aadi Bioscience Announces Exploratory Biomarker Data from Patients in Its AMPECT Trial and Expanded Access Program to be Presented at 2022 ASCO Annual Meeting Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations regardless of prior mTOR inhibitor exposure LOS ANGELES, May 26, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes, today announced presentat...

May 26, 2022 1 EN
 PRESS RELEASE
Free
ARPO Aerpio Pharmace...

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Co...

Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference LOS ANGELES, May 18, 2022 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (Nasdaq: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced that Founder, Chief Executive Officer and President, Neil Desai, Ph.D., and senior members of Aadi’s executive team will participate virtually in the H.C. Wainwright Global Investment Conference, to be held in person and virtually May 23-26, 2022 in Mia...

May 18, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch